Alembic Pharmaceuticals reported a 12.1% year-on-year rise in consolidated net profit for the first quarter, with earnings reaching ₹173.07 crore for the period ended June. In the same quarter last year, the company had posted a consolidated net profit of ₹154.38 crore.
The drugmaker said the increase came on the back of broad-based growth across its businesses. The result points to steady momentum in the company’s operations at the start of the new fiscal year.
Alembic Pharma’s Q1 performance will be watched closely by investors tracking the pharmaceutical sector, especially as companies navigate demand trends across domestic and international markets. A double-digit profit increase suggests the company was able to improve earnings despite a competitive environment.
With the June quarter now reported, the focus is likely to remain on whether Alembic Pharmaceuticals can sustain this growth trajectory in the coming quarters. The latest numbers offer an early sign of resilience in its overall business mix.
